HealthcareNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1701108SPRO stock profile & AI dashboard →

13F Pro Quality Score

19.5/100

Rank #2,690 of 2,860 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.2/100

Profitability

0.1/100

Balance Sheet

4.1/100

Earnings Quality

30.0/100

Free Cash Flow

99.9/100

Institutional Flow

24.9/100

Dilution Risk

22.3/100

SPRO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Spero Therapeutics, Inc. (SPRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRO at 19.5/100 on a 32-signal composite quality model, placing it at rank #2,690 of 2,860 stocks — the bottom half of the AI-ranked universe. SPRO scores in the top quartile across free cash flow (99.9). Areas of concern include profitability (0.1) and revenue growth (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Spero Therapeutics, Inc. reports quarterly revenue of $258.0K, net income of $-7.2M, free cash flow of $15.9M. Top institutional holders of SPRO by reported 13-F value include GSK plc, PFIZER, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SPRO trades on the Nasdaq exchange and files with the SEC under CIK 1701108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Spero Therapeutics, Inc. directly from SEC EDGAR. Spero Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 44 since 2021, currently 19.5 — a stable long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q1 2026

$258.0K

Net Income

Q1 2026

$-7.2M

Free Cash Flow

Q1 2026

$15.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+94.0% YoY
$103.8MFY 2023
FY20 $9.3MFY21 $18.3MFY22 $53.5MFY23 $103.8M

Net Income

$22.8MFY 2023
FY20 $-78.3MFY21 $-89.8MFY22 FY23 $22.8M

Operating Income

+150.9% YoY
$21.5MFY 2023
FY20 $-79.1MFY21 $-88.0MFY22 $-42.2MFY23 $21.5M

EPS (Diluted)

+135.0% YoY
$0.43FY 2023
FY20 FY21 $-2.91FY22 $-1.23FY23 $0.43

Total Assets

+46.1% YoY
$182.4MFY 2023
FY20 $153.5MFY21 $171.1MFY22 $124.8MFY23 $182.4M

Op. Cash Flow

-326.8% YoY
$-33.0MFY 2023
FY20 $-85.9MFY21 $-64.3MFY22 $-7.7MFY23 $-33.0M

Track SPRO with AI-powered research

10 AI analysts debate this stock daily. Free to start.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Spero Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of SPRO

Unlock Full Research for SPRO

Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for Spero Therapeutics, Inc. and 2,800+ other companies.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SPRO a good stock to buy?

13F Pro's AI-powered analysis of Spero Therapeutics, Inc. (SPRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SPRO are available on the SPRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SPRO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SPRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Spero Therapeutics, Inc.'s investment landscape.